A citation-based method for searching scientific literature

Katherine R Tuttle, Frank C Brosius, Matthew A Cavender, Paola Fioretto, Kevin J Fowler, Hiddo J L Heerspink, Tom Manley, Darren K McGuire, Mark E Molitch, Amy K Mottl, Leigh Perreault, Sylvia E Rosas, Peter Rossing, Laura Sola, Volker Vallon, Christoph Wanner, Vlado Perkovic. Am J Kidney Dis 2021
Times Cited: 7







List of co-cited articles
5 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
370
42

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
42

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
290
28

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
28

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
492
28

Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis.
Natriuretic Peptides Studies Collaboration, Peter Willeit, Stephen Kaptoge, Paul Welsh, Adam Butterworth, Rajiv Chowdhury, Sarah Spackman, Lisa Pennells, Pei Gao, Stephen Burgess,[...]. Lancet Diabetes Endocrinol 2016
90
14

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
812
14

Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
James L Januzzi, Javed Butler, Petr Jarolim, Naveed Sattar, Ujjwala Vijapurkar, Mehul Desai, Michael J Davies. J Am Coll Cardiol 2017
80
14

Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Aaron Y Kluger, Kristen M Tecson, Andy Y Lee, Edgar V Lerma, Janani Rangaswami, Norman E Lepor, Michael E Cobble, Peter A McCullough. Cardiovasc Diabetol 2019
56
14


Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Michael E Nassif, Sheryl L Windsor, Fengming Tang, Yevgeniy Khariton, Mansoor Husain, Silvio E Inzucchi, Darren K McGuire, Bertram Pitt, Benjamin M Scirica, Bethany Austin,[...]. Circulation 2019
110
14

Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure.
Claire Sweeney, Fiona Ryan, Mark Ledwidge, Cristin Ryan, Ken McDonald, Chris Watson, Rebabonye B Pharithi, Joe Gallagher. Cochrane Database Syst Rev 2019
2
50

Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.
Hiddo J L Heerspink, Avraham Karasik, Marcus Thuresson, Cheli Melzer-Cohen, Gabriel Chodick, Kamlesh Khunti, John P H Wilding, Luis Alberto Garcia Rodriguez, Lucia Cea-Soriano, Shun Kohsaka,[...]. Lancet Diabetes Endocrinol 2020
75
14

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs.
Guntram Schernthaner, Avraham Karasik, Agnė Abraitienė, Alexander S Ametov, Zsolt Gaàl, Janusz Gumprecht, Andrej Janež, Susanne Kaser, Katarina Lalić, Boris N Mankovsky,[...]. Cardiovasc Diabetol 2019
5
20

Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.
James L Januzzi, Jialin Xu, JingWei Li, Wayne Shaw, Richard Oh, Michael Pfeifer, Javed Butler, Naveed Sattar, Kenneth W Mahaffey, Bruce Neal,[...]. J Am Coll Cardiol 2020
11
14

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Elisabetta Patorno, Ajinkya Pawar, Jessica M Franklin, Mehdi Najafzadeh, Anouk Déruaz-Luyet, Kimberly G Brodovicz, Steven Sambevski, Lily G Bessette, Adrian J Santiago Ortiz, Martin Kulldorff,[...]. Circulation 2019
79
14

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Shun Kohsaka, Carolyn S P Lam, Dae Jung Kim, Matthew A Cavender, Anna Norhammar, Marit E Jørgensen, Kåre I Birkeland, Reinhard W Holl, Josep Franch-Nadal, Navdeep Tangri,[...]. Lancet Diabetes Endocrinol 2020
22
14

Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis.
Richard W Troughton, Christopher M Frampton, Hans-Peter Brunner-La Rocca, Matthias Pfisterer, Luc W M Eurlings, Hans Erntell, Hans Persson, Christopher M O'Connor, Deddo Moertl, Patric Karlström,[...]. Eur Heart J 2014
170
14

Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE).
Atsushi Tanaka, Itaru Hisauchi, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Hirofumi Tomiyama, Masataka Sata, Shinichiro Ueda, Jun-Ichi Oyama, Masafumi Kitakaze,[...]. ESC Heart Fail 2020
14
14

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett,[...]. Circulation 2019
133
14

SGLT2i: beyond the glucose-lowering effect.
Lihua Ni, Cheng Yuan, Guopeng Chen, Changjiang Zhang, Xiaoyan Wu. Cardiovasc Diabetol 2020
14
14

An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
Jie Yu, Zien Zhou, Kenneth W Mahaffey, David R Matthews, Brendon L Neuen, Hiddo J L Heerspink, Meg J Jardine, JingWei Li, Vlado Perkovic, Bruce Neal,[...]. Int J Cardiol 2021
3
33

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
291
14

Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Edmund Ym Chung, Marinella Ruospo, Patrizia Natale, Davide Bolignano, Sankar D Navaneethan, Suetonia C Palmer, Giovanni Fm Strippoli. Cochrane Database Syst Rev 2020
7
14


Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Johannes F E Mann, Roland E Schmieder, Matthew McQueen, Leanne Dyal, Helmut Schumacher, Janice Pogue, Xingyu Wang, Aldo Maggioni, Andrzej Budaj, Suphachai Chaithiraphan,[...]. Lancet 2008
14

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.
Bertram Pitt, Lars Kober, Piotr Ponikowski, Mihai Gheorghiade, Gerasimos Filippatos, Henry Krum, Christina Nowack, Peter Kolkhof, So-Young Kim, Faiez Zannad. Eur Heart J 2013
227
14

Combined angiotensin inhibition for the treatment of diabetic nephropathy.
Linda F Fried, Nicholas Emanuele, Jane H Zhang, Mary Brophy, Todd A Conner, William Duckworth, David J Leehey, Peter A McCullough, Theresa O'Connor, Paul M Palevsky,[...]. N Engl J Med 2013
614
14

Sodium zirconium cyclosilicate in hyperkalemia.
David K Packham, Henrik S Rasmussen, Philip T Lavin, Mohamed A El-Shahawy, Simon D Roger, Geoffrey Block, Wajeh Qunibi, Pablo Pergola, Bhupinder Singh. N Engl J Med 2015
241
14

Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors.
Matthew R Weir, George L Bakris, David A Bushinsky, Martha R Mayo, Dahlia Garza, Yuri Stasiv, Janet Wittes, Heidi Christ-Schmidt, Lance Berman, Bertram Pitt. N Engl J Med 2015
334
14

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
George L Bakris, Rajiv Agarwal, Juliana C Chan, Mark E Cooper, Ron T Gansevoort, Hermann Haller, Giuseppe Remuzzi, Peter Rossing, Roland E Schmieder, Christina Nowack,[...]. JAMA 2015
266
14

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph,[...]. N Engl J Med 2020
112
14

The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.
Yuliya Lytvyn, Petter Bjornstad, Daniel H van Raalte, Hiddo L Heerspink, David Z I Cherney. Endocr Rev 2020
20
14

Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
Sadayoshi Ito, Naoki Kashihara, Kenichi Shikata, Masaomi Nangaku, Takashi Wada, Yasuyuki Okuda, Tomoko Sawanobori. Clin J Am Soc Nephrol 2020
10
14

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Hans-Henrik Parving, Barry M Brenner, John J V McMurray, Dick de Zeeuw, Steven M Haffner, Scott D Solomon, Nish Chaturvedi, Frederik Persson, Akshay S Desai, Maria Nicolaides,[...]. N Engl J Med 2012
753
14

Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.
Annabelle M Warren, Søren T Knudsen, Mark E Cooper. Expert Opin Ther Targets 2019
47
14

Renal lesions predict progression of diabetic nephropathy in type 1 diabetes.
M Luiza Caramori, Alicia Parks, Michael Mauer. J Am Soc Nephrol 2013
60
14

Activin A is a potent activator of renal interstitial fibroblasts.
Shin Yamashita, Akito Maeshima, Itaru Kojima, Yoshihisa Nojima. J Am Soc Nephrol 2004
101
14

Activins and Inhibins: Roles in Development, Physiology, and Disease.
Maria Namwanje, Chester W Brown. Cold Spring Harb Perspect Biol 2016
73
14

Molecular mechanisms of diabetic kidney disease.
Kimberly Reidy, Hyun Mi Kang, Thomas Hostetter, Katalin Susztak. J Clin Invest 2014
355
14

Physiological roles of Rho and Rho effectors in mammals.
Dean Thumkeo, Sadanori Watanabe, Shuh Narumiya. Eur J Cell Biol 2013
145
14

Attenuation of bleomycin-induced pulmonary fibrosis by follistatin.
Fumiaki Aoki, Masahiko Kurabayashi, Yoshihisa Hasegawa, Itaru Kojima. Am J Respir Crit Care Med 2005
84
14

ROCK2 regulates TGF-β-induced expression of CTGF and profibrotic genes via NF-κB and cytoskeleton dynamics in mesangial cells.
Yosuke Nagai, Keiichiro Matoba, Daiji Kawanami, Yusuke Takeda, Tomoyo Akamine, Sho Ishizawa, Yasushi Kanazawa, Tamotsu Yokota, Kazunori Utsunomiya, Rimei Nishimura. Am J Physiol Renal Physiol 2019
17
14

The caveolin-1 regulated protein follistatin protects against diabetic kidney disease.
Dan Zhang, Agata L Gava, Richard Van Krieken, Neel Mehta, Renzhong Li, Bo Gao, Eric M Desjardins, Gregory R Steinberg, Thomas Hawke, Joan C Krepinsky. Kidney Int 2019
7
14

Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy.
James Voelker, Paul H Berg, Matthew Sheetz, Kevin Duffin, Tong Shen, Brian Moser, Tom Greene, Samuel S Blumenthal, Ivan Rychlik, Yoram Yagil,[...]. J Am Soc Nephrol 2017
105
14

MEKK1 transduces activin signals in keratinocytes to induce actin stress fiber formation and migration.
Lin Zhang, Maoxian Deng, Ranjani Parthasarathy, Lei Wang, Maureen Mongan, Jeffery D Molkentin, Yi Zheng, Ying Xia. Mol Cell Biol 2005
87
14

RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease.
Fangfang Peng, Dongcheng Wu, Bo Gao, Alistair J Ingram, Baifang Zhang, Katherine Chorneyko, Rick McKenzie, Joan C Krepinsky. Diabetes 2008
136
14

The role of MTJ-1 in cell surface translocation of GRP78, a receptor for alpha 2-macroglobulin-dependent signaling.
Uma Kant Misra, Mario Gonzalez-Gronow, Govind Gawdi, Salvatore Vincent Pizzo. J Immunol 2005
77
14

The Role of the Rho/ROCK Pathway in Ang II and TGF-β1-Induced Atrial Remodeling.
Li-Juan Liu, Feng-Juan Yao, Gui-Hua Lu, Cheng-Gui Xu, Zhe Xu, Kai Tang, Yun-Jiu Cheng, Xiu-Ren Gao, Su-Hua Wu. PLoS One 2016
16
14



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.